Abstract: According to one embodiment, a chemical sensor kit includes a chemical sensor and a reagent. The chemical sensor includes a substrate and a channel which includes hexagonal crystal lattices composed of carbon atoms which are arranged on a surface of the substrate. A first substance is fixed to the channel. The reagent includes a second substance labeled with a fluorescent dye. Either one of the first substance or the second substance is a capturing body that has a specific binding ability to a target substance. And the other is a competing substance which has a binding ability to the capturing body and competes with the target substance for binding to the capturing body.

Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.

Abstract: The present invention relates to a polypeptide carrying a human BNP(1-32) epitope according to Formula (I): a1-R1-X1-FGRKMDR-X2-R2-a2 as well as ligands specific of the FGRKMDR epitope.

Abstract: The present invention relates a to method for preparing a biological sample for use in an immunolabeling process. The invention also relates to corresponding kits for use in the immunolabeling process. The method comprises the following steps: —labeling the biological sample with a labeling component, the labeling component provided with a first enhancer antigen, and —providing a first enhancer antibody, the first enhancer antibody selected to solely bind to the first enhancer antigen, wherein the first enhancer antigen is a non-biological peptide containing one or more “non-natural” amino acids and is not present in the immunolabeling process.

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

Abstract: The invention relates to a method of determining the dissociation rate constant (koff) of a receptor molecule R on a target cell using a combination of reversible and irreversible cell labeling. The invention further relates to a cell comprising such a receptor molecule R, wherein the cell has bound to it such a combination of cell labeling. The invention further relates to a kit and an apparatus useful in performing the methods of the invention. The invention further relates to a method of isolation a high-avidity T cell.

Abstract: A multiplexed digital detection platform embodiment for molecular species in solution is based on a single-molecule immunochemistry, and/or aptamer chemistry, on color-barcoded beads. Beads that capture molecular species from a complex sample using selective binders are exposed to a test sample, and the captured molecular species is tagged using second affinity probes that are linked to photocleavable nucleic acid particles. In the embodiment, the beads are then introduced to a counter system that comprises a microcavity/nanopore device. Once a bead is captured by the micropore, nucleic acid particles, e.g., reporter nucleic acid nanoparticles (rNANPs), are released using photocleavage, and are detected by the nanopore. Each electrical spike that is uniquely produced by the nucleic acid nanoparticle is counted as a single molecular species, and the total count represents the overall number of molecular species in the sample. Various molecular species can be detected at the same time.

Abstract: Immunoglobulin light chain proteins are used to generate synthetic fibrils in vitro. The fibrils are mixed with immunoglobulin light chain proteins from a biological sample. In either a direct binding assay, competition assay, or dilution-based competition assay, a signal is detected from the mixture. The intensity of the detectable signal relates to the level of binding between the immunoglobulin light chain proteins to the fibrils and can thus be used to identify amyloidogenic immunoglobulin light chain proteins in a biological sample of the subject and to assess amyloidogenic risk to a subject. For example, the signal intensities from the assays can be used in a comparison to one or more threshold (control) values derived from samples of known light chain types or in the absence of light chains. The comparisons permit identification of amyloidogenic proteins, assessment of amyloidogenic risk, and categorization of the subject into an appropriate “at risk” group.

Abstract: Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.

Abstract: The invention provides anti-idiotypic antibodies against anti-PD-L1 antibodies and methods of using the same.

Abstract: The present invention relates to mutants of S100A12 having at least one mutation in the high-affinity calcium binding hand or the low-affinity calcium binding hand or the zinc binding region. The present invention also relates to methods of detecting S100A12 dimers in a sample as well as methods of diagnosis using the S100A12 mutant of the invention, as well as to diagnostic compositions and kits comprising such an S100A12 mutant. The present invention further relates to a method of generating an antibody that specifically binds to an S100A12 dimer using the S100A12 mutant of the invention, as well as to an antibody that specifically binds to an S100A12 dimer.

Abstract: Provided are methods of predicting responsiveness of a subject having an inflammatory bowel disease (IBD) to a tumor necrosis factor (TNF)-alpha inhibitor, by analyzing a frequency of at least one subpopulation of immune cells in a tissue biopsy of the subject. Also provided are methods of selecting a treatment for a subject and kits for determining responsiveness of the subject to treatment with a TNF-alpha inhibitor.

Abstract: The present invention relates to a method for detecting an aggregate of an aggregate-forming polypeptide of a biosample, comprising (a) a step of spiking a dimer type of the aggregate-forming polypeptide into the biosample to be analyzed; (b) a step of incubating a resultant product of step (a) to further form an aggregate of the aggregate-forming polypeptide; (c) a step of contacting a resultant product of step (b) with a binding agent-tag in which a signal-generating tag is bound to a binding agent that binds to the aggregate of the aggregate-forming polypeptide; and (d) a step of detecting a signal which is generated from the binding agent-tag bound to the aggregate of the aggregate-forming polypeptide.

Abstract: The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCGbeta, and at least one biomarker selected from FSTL3, sTNFR1, PIGF2, Activin A, uE3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.

Abstract: The present invention is directed to methods for reducing cross-reactivity between species employed in multiplexed immunoassays.

Abstract: The present invention relates to compositions and methods use in designing immunoassay controls. In various aspects, the invention provides synthetic peptides comprising the sequence CPRRPYIL or an analog thereof; ELAGLGFAELQC or an analog thereof; and CDWRKNIDAL or an analog thereof; specific binding reagents that bind to a CPRRPYIL, ELAGLGFAELQC or CDWRKNIDAL peptide; methods of producing such reagents; and assays utilizing such reagents to provide assay controls signals that are unrelated to the measurement of the analyte or analytes of interest in that no reagents used in the analyte assay(s) contribute to the control signal.

Abstract: An immunoassay includes forming first mixtures by reacting a combination reagent with serum of a subject; simultaneously forming second mixtures by reacting randomly selected platelet samples with the serum wherein in each mixture there are immunity compounds formed by combining the platelet antigens with predetermined antibodies in the serum, and other platelet antigens and other antibodies in the serum not forming the immunity compounds; preparing an interception device including receptacles and a filter net; placing each mixture in one receptacle; washing the mixtures wherein the mixtures forming the immunity compounds are intercepted by the filter net with others passing through; adding a signal sensing reagent to each receptacle; reacting the signal sensing reagent with the intercepted mixtures forming the immunity compounds to form final products; and performing a signal sensing to determine whether the final products contain anti-platelet antibodies and determine compatibility of cross matching of resp

Abstract: The invention relates to a method for detecting and measuring the presence of nucleosome-protein adducts and the use of such measurements for the detection and diagnosis of disease. The invention also relates to a method of identifying nucleosome adduct biomarkers for the detection and diagnosis of disease and to biomarkers identified by said method.

Abstract: Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest.

Abstract: Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK18 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unbo